Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence

2021 ◽  
Vol 13 (623) ◽  
Author(s):  
Afroditi Katsarou ◽  
Maria Sjöstrand ◽  
Jyoti Naik ◽  
Jorge Mansilla-Soto ◽  
Dionysia Kefala ◽  
...  
2021 ◽  
pp. 101097
Author(s):  
Hanzeng Li ◽  
Bruce S. Hostager ◽  
Tina Arkee ◽  
Gail A. Bishop

2004 ◽  
Vol 5 (8) ◽  
pp. 791-799 ◽  
Author(s):  
Qi-Jing Li ◽  
Aaron R Dinner ◽  
Shuyan Qi ◽  
Darrell J Irvine ◽  
Johannes B Huppa ◽  
...  

2018 ◽  
Author(s):  
Paula Kroon ◽  
Elselien Frijlink ◽  
Victoria Iglesias-Guimarais ◽  
Andriy Volkov ◽  
Marit M van Buuren ◽  
...  

AbstractTo increase cancer immunotherapy success, PD-1 blockade must be combined with rationally selected treatments. Here, we examined in a poorly immunogenic mouse breast cancer model the potential of antibody-based immunomodulation and conventional anti-cancer treatments to collaborate with anti-PD-1 treatment. One important requirement to improve anti-PD-1-mediated tumor control was to promote tumor-specific cytotoxic T cell (CTL) priming, which was achieved by stimulating the CD137 costimulatory receptor. A second requirement was to overrule PD-1-unrelated mechanisms of CTL suppression in the tumor micro-environment (TME). This was achieved by radiotherapy and cisplatin treatment. In the context of CD137/PD-1-targeting immunotherapy, radiotherapy allowed for tumor elimination by altering the TME, rather than intrinsic CTL functionality. Combining this radioimmunotherapy regimen with low-dose cisplatin improved CTL-dependent regression of a contralateral tumor outside the radiation field. Thus, systemic tumor control may be achieved by combining immunotherapy protocols that promote T cell priming with (chemo)radiation protocols that permit CTL activity in both the irradiated tumor and (occult) metastases.Summary statementThis study reveals that radiotherapy and cisplatin can be ‘re-purposed’ to improve antibody-based immunotherapy success in poorly immunogenic breast cancer by overruling PD-1 unrelated mechanisms of T cell suppression in the tumor micro-environment.


Blood ◽  
2008 ◽  
Vol 111 (3) ◽  
pp. 1378-1386 ◽  
Author(s):  
Young-June Kim ◽  
Myung-Kwan Han ◽  
Hal E. Broxmeyer

Abstract Ligation of NKG2D, a potent costimulatory receptor, can be either beneficial or detrimental to CD8+ cytotoxic T cell (CTL) responses. Factors for these diverse NKG2D effects remain elusive. In this study, we demonstrate that 4-1BB, another costimulatory receptor, is an essential regulator of NKG2D in CD8+ T cells. Costimulation of NKG2D caused down-modulation of NKG2D, but induced 4-1BB expression on the cell surface, even in the presence of TGF-β1, which inhibits 4-1BB expression. Resulting NKG2D−4-1BB+ cells were activated but still in an immature state with low cytotoxic activity. However, subsequent 4-1BB costimulation induced cytotoxic activity and restored down-modulated NKG2D. The cytotoxic activity and NKG2D expression induced by 4-1BB on NKG2D+4-1BB+ cells were refractory to TGF-β1 down-modulation. Such 4-1BB effects were enhanced by IL-12. In contrast, in the presence of IL-4, 4-1BB effects were abolished because IL-4 down-modulated NKG2D and 4-1BB expression in cooperation with TGF-β1, generating another CD8+ T-cell type lacking both NKG2D and 4-1BB. These NKG2D−4-1BB− cells were inert and unable to gain cytotoxic activity. Our results suggest that 4-1BB plays a critical role in protecting NKG2D from TGF-β1–mediated down-modulation. Co-expression of NKG2D and 4-1BB may represent an important biomarker for defining competency of tumor infiltrating CD8+ T cells.


2008 ◽  
Vol 48 (supplement) ◽  
pp. S75
Author(s):  
Yasutomo Inui ◽  
Kunitake Higo ◽  
Hisayuki Morii ◽  
Takahisa Ikegami ◽  
Ryo Abe ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document